A team of scientists led by Weill Cornell Medical College researchers says that a new drug is offering dramatic cure rates for hepatitis C patients with two subtypes of the infection - genotype 2 and 3. These two subtypes account for approximately 25 percent of hepatitis C infection in the United States. The drug, called sofosbuvir, offers more effective treatment for most patients studied in a Phase 3 clinical trial who had no other treatment options, ...Saturday, 27 April 2013
Sofosbuvir Therapy Linked to High Cure Rate for 2 Hepatitis C Subtypes
A team of scientists led by Weill Cornell Medical College researchers says that a new drug is offering dramatic cure rates for hepatitis C patients with two subtypes of the infection - genotype 2 and 3. These two subtypes account for approximately 25 percent of hepatitis C infection in the United States. The drug, called sofosbuvir, offers more effective treatment for most patients studied in a Phase 3 clinical trial who had no other treatment options, ...
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment